Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS:

* Histologically confirmed CD20+ non-Hodgkin's lymphoma

  * Disease is refractory, relapsed, or in remission
* Measurable or evaluable disease

PATIENT CHARACTERISTICS:

Performance status

* ECOG 0-2

Life expectancy

* Not specified

Hematopoietic

* Hemoglobin \> 8 g/dL
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 50,000/mm\^3

Hepatic

* Bilirubin ≤ 2.0 mg/dL
* SGOT or SGPT ≤ 2.5 times normal
* No history of severe hepatic dysfunction

Renal

* Creatinine ≤ 2.0 mg/dL OR
* Creatinine clearance ≥ 60 mL/min
* No uncompensated major adrenal dysfunction
* BUN \< 1.5 times normal

Cardiovascular

* No severe cardiac dysfunction
* No major heart disease
* LVEF ≥ 50% by MUGA
* No uncontrolled hypertension
* No congenital or acquired heart disease or cardiac arrhythmias unless cardiac consult and evaluation are done

Pulmonary

* DLCO ≥ 50% of normal
* No symptomatic obstructive or restrictive disease

Other

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No active infections
* HIV negative
* No significant skin breakdown from tumor or other diseases
* Dental evaluation and teeth cleaning with no potential sources of infection required
* No uncompensated major thyroid dysfunction

PRIOR CONCURRENT THERAPY:

Biologic therapy

* No prior stem cell transplantation

Chemotherapy

* No prior total doxorubicin or daunorubicin dose ≥ 450 mg/m\^2 unless endomyocardial biopsy shows \< grade 2 drug effect AND ejection fraction ≥ 50% by gated blood pool scan

Endocrine therapy

* No concurrent hormonal therapy except steroids for adrenal failure, septic shock, or pulmonary toxicity or hormones for non-disease-related conditions (e.g., insulin for diabetes)